V 24343

Drug Profile

V 24343

Alternative Names: V24343

Latest Information Update: 02 Aug 2011

Price : $50

At a glance

  • Originator Vernalis
  • Class Obesity therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 17 Sep 2007 Preliminary results from a phase I clinical trial in overweight and obese volunteers added to the adverse events and Obesity therapeutic trials sections
  • 17 Sep 2007 Vernalis completes a phase I trial in obesity in united Kingdom
  • 11 Dec 2006 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top